The company develops blood glucose sensors that rely on ultrasonic, electromagnetic and thermal scans rather than blood tests. Integrity’s flagship GlucoTrack devices relies on a tiny sensor that clips to the earlobe, using a combination of metrics to determine blood glucose based on physiological changes in the body.
Integrity won CE Mark approval in the European Union last year for its DF-F model, but the device has yet to reach the U.S. market. The technology will have to go through the FDA’s stringent premarket approval pathway.
The new funding was raised through sales of more than 3,000 units, which were comprised of 1 share of Series B 5.5% convertible preferred stock, a 5-year warrant to purchase shares at $5.80 apiece and a 5-year warrant to purchase shares at $10 apiece. Each unit sold for $1,000, according to an Integrity press release.
Registration is open for DeviceTalks Boston! Join us on June 5-6, 2019, as we explore the trends and technology that are shaping the future of the medical device industry.